Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

Nature Medicine

Volumn 21, Issue 9, 2015, Pages 1065-1070

  Yassine, Hadi M ^a   Boyington, Jeffrey C ^a   McTamney, Patrick M ^a,d   Wei, Chih Jen ^a,e   Kanekiyo, Masaru ^a   Kong, Wing Pui ^a   Gallagher, John R ^a   Wang, Lingshu ^a   Zhang, Yi ^a   Joyce, M Gordon ^a   Lingwood, Daniel ^a,f   Moin, Syed M ^a   Andersen, Hanne ^b   Okuno, Yoshinobu ^c   Rao, Srinivas S ^a   Harris, Audray K ^a   Kwong, Peter D ^a   Mascola, John R ^a   Nabel, Gary J ^a,e   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOQUAL INC   (United States)

^c The Research Foundation for Microbial Diseases of Osaka University   (Japan)

^d MEDIMMUNE   (United States)

^e SANOFI   (United States)

^f Koch Institute for Integrative Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; FERRITIN; IMMUNOGLOBULIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; NANOPARTICLE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CRYSTAL STRUCTURE; FERRET; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; VIRUS IMMUNITY; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; FEMALE; IMMUNOLOGY; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; VACCINATION;

EID: 84941023600     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3927     Document Type: Article

References (48)

1. Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).
2. Ekiert, D.C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
3. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
4. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
5. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348 (2012).
6. Nakamura, G. et al. An in vivo human plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14, 93-103 (2013).
7. Tan, K., Liu, J.H., Wang, J.H., Shen, S. & Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94, 12303-12308 (1997).
8. Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552-2558 (1993).
9. Dreyfus, C., Ekiert, D.C. & Wilson, I.A. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 hemagglutinin. J. Virol. 87, 7149-7154 (2013).
10. Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102-106 (2013).
11. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
12. Novak, E.J. & Rabinovitch, P.S. Improved sensitivity in flow cytometric intracellular ionized calcium measurement using fluo-3/Fura Red fluorescence ratios. Cytometry 17, 135-141 (1994).
13. Lingwood, D. et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489, 566-570 (2012).
14. O'Hagan, D.T., Ott, G.S., Van Nest, G., Rappuoli, R. & Del Giudice, G. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert Rev. Vaccines 12, 13-30 (2013).
15. Wei, C.J. et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Transl. Med. 2, 24ra21 (2010).
16. DiLillo, D.J., Tan, G.S., Palese, P. & Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc-R interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
17. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190, 1837-1848 (2013).
18. Jegaskanda, S., Weinfurter, J.T., Friedrich, T.C. & Kent, S.J. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87, 5512-5522 (2013).
19. Jegaskanda, S., Reading, P.C. & Kent, S.J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 193, 469-475 (2014).
20. Sagawa, H., Ohshima, A., Kato, I., Okuno, Y. & Isegawa, Y. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 77, 1483-1487 (1996).
21. Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1, e00018-10 (2010).
22. Bommakanti, G. et al. Design of an HA2-based Escherichia coli-expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. USA 107, 13701-13706 (2010).
23. Bommakanti, G. et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J. Virol. 86, 13434-13444 (2012).
24. Lu, Y., Welsh, J.P. & Swartz, J.R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. USA 111, 125-130 (2014).
25. Mallajosyula, V.V.A. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. USA 111, E2514-E2523 (2014).
26. Krammer, F. et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88, 3432-3442 (2014).
27. Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542-6550 (2013).
28. Kong, W.P. et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. USA 103, 15987-15991 (2006).
29. Xiang, Z., Soto, C.S. & Honig, B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. Proc. Natl. Acad. Sci. USA 99, 7432-7437 (2002).
30. Xiang, Z. & Honig, B. Extending the accuracy limits of prediction for side-chain conformations. J. Mol. Biol. 311, 421-430 (2001).
31. Kleywegt, G.J., Zou, J.Y., Kjeldgaard, M. & Jones, T.A. in International Tables for Crystallography Vol. F (eds. Rossmann, M.G. & Arnold, E.) 353-367 (Kluwer Academic Publishers, Dordrecht, the Netherlands, 2001).
32. Kellogg, E.H., Leaver-Fay, A. & Baker, D. Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins 79, 830-838 (2011).
33. Pettersen, E.F. et al. UCSF chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
34. Wei, C.J. et al. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 4, 147ra114 (2012).
35. Ofek, G. et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004).
36. Majeed, S. et al. Enhancing protein crystallization through precipitant synergy. Structure 11, 1061-1070 (2003).
37. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Meth. Enzymol. 276, 307-326 (1997).
38. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
39. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
40. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
41. Adams, P.D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948-1954 (2002).
42. Mindell, J.A. & Grigorieff, N. Accurate determination of local defocus and specimen tilt in electron microscopy. J. Struct. Biol. 142, 334-347 (2003).
43. Scheres, S.H.W. A Bayesian view on cryo-EM structure determination. J. Mol. Biol. 415, 406-418 (2012).
44. Luo, X.M. et al. Engineering human hematopoietic stem and progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113, 1422-1431 (2009).
45. Whittle, J.R.R. et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J. Virol. 88, 4047-4057 (2014).
46. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
47. Wei, C.J. et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064 (2010).
48. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals 8th edn. (National Academies Press, Washington, DC, USA, 2011).